Product Description

The Urine Pre-Clinical CartiLaps^® (CTX-II) EIA detects degradation products of C-terminal telopeptides of type II collagen (CTX-II) in non-human urine and cell culture supernatant. The test is intended for research use only and not for use in diagnostic procedures.

Key Features and Values

Unique Features

• Animal Models of Rheumatoid Arthritis and Osteoarthritis
• Easy, non-invasive quantification of cartilage degradation
• Strong association to indexes of joint damage, e.g. cartilage erosion
• Demonstration of Chondroprotective Effect of Drugs
• Rapid response to chondroprotective drugs (within 1-2 weeks)
• Early response in CTX-II is highly correlated to histological endpoints³
• CTX-II can be quantified in relevant cartilage explant culture supernatant human origin and animal models
• CTX-II is elevated in both RA and OA rat models
• CTX-II levels are associated with disease activity in RA and OA, primarily indexes of structural damage²
• Useful for dynamic monitoring of cartilage in multiple species
• A complete assay panel supporting bone and cartilage research

Scientific Description

Disruption of the structural integrity of cartilage is the major histological finding in osteoarthritis and rheumatoid arthritis.

Type II collagen is the major organic constituent of cartilage. Fragments of type II collagen (CTX-II) are being released into circulation and subsequently secreted into urine following degradation of cartilage. In non-human urine, the CTX-II fragments can be quantified by Urine Pre-Clinical CartiLaps^® EIA, which in addition is applicable for cell culture supernatants¹.

Publications